Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Annexin Pharmaceuticals

13.10 SEK-2.96 %9/9 17:29
Less than 1K followers

ANNX

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
-2.96 %
+3.56 %
+2.29 %
-8.29 %
-32.84 %
-52.51 %
-67.89 %
-86.27 %
-95.84 %

Annexin Pharmaceuticals is a biotechnology company developing the drug candidate ANXV, based on the protein Annexin A5, for the treatment of diseases such as vascular damage, inflammation and certain cancers. The company's partners are healthcare providers and biopharmaceutical companies and the business is aimed at global markets through research and licensing collaborations. The company was founded in 2014 and is headquartered in Stockholm, Sweden.

Read more
Market cap
114.21M SEK
Turnover
65.51K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Press releases
ShowingAll content types

Financial calendar
22/10
2026

Interim report Q3'26

11/2
2027

Annual report '26

Press release2026-08-25 17:35

Redeye: Annexin (Q2 Review): Further data expected in H2

Annexin Pharmaceuticals
Press release2026-08-21 08:33

Investor Studios: Annexin Pharmaceuticals VD presenterar kvartalet live 09.30

Annexin Pharmaceuticals
Regulatory press release2026-08-21 08:30

Annexin Pharmaceuticals halvårsrapport januari – juni 2026

Annexin Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2026-08-21 08:00

Annexin advances the NEXUS study to include patients who received an anti-VEGF injection

Annexin Pharmaceuticals
Press release2026-08-21 08:00

Annexin driver NEXUS-studien vidare genom att inkludera patienter som fått en anti-VEGF-injektion

Annexin Pharmaceuticals
Press release2026-08-20 08:30

Annexin Pharmaceuticals erhåller det internationella generiska namnet vanexin för läkemedelskandidaten ANXV

Annexin Pharmaceuticals
Press release2026-08-20 08:30

Annexin Pharmaceuticals receives the International Nonproprietary Name (INN) vanexin for the drug candidate ANXV

Annexin Pharmaceuticals
Press release2026-08-13 12:00

Inbjudan till presentation av Annexins delårsrapport för andra kvartalet 2026

Annexin Pharmaceuticals
Press release2026-07-21 08:30

Annexin uppdaterar om nio patienter behandlade i NEXUS-studien

Annexin Pharmaceuticals
Press release2026-07-21 08:30

Annexin updates on nine patients treated in NEXUS study

Annexin Pharmaceuticals
Regulatory press release2026-07-03 13:15

Annexins företrädesemission 98 procent tecknad

Annexin Pharmaceuticals
Regulatory press release2026-07-03 13:15

Annexin's rights issue 98 percent subscribed

Annexin Pharmaceuticals
Press release2026-06-23 10:00

Investor Studios: Annexin Pharmaceuticals om NEXUS-studien och företrädesemission

Annexin Pharmaceuticals
Press release2026-06-23 08:30

Annexin uppdaterar om fortsatt lovande data från NEXUS studien – som visar på förbättrad blodförsörjning i näthinnan i både DR och RVO

Annexin Pharmaceuticals
Press release2026-06-23 08:30

Annexin updates on continuous promising data from the NEXUS study – demonstrating improvement of retinal perfusion in both DR and RVO

Annexin Pharmaceuticals
Regulatory press release2026-06-15 08:30

Idag börjar teckningsperioden i Annexin Pharmaceuticals företrädesemission

Annexin Pharmaceuticals
Regulatory press release2026-06-15 08:30

The subscription period in Annexin Pharmaceuticals’ rights issue begins today

Annexin Pharmaceuticals
Regulatory press release2026-06-10 08:30

Annexin Pharmaceuticals offentliggör Informationsdokument med anledning av förestående företrädesemission

Annexin Pharmaceuticals
Regulatory press release2026-06-10 08:30

Annexin Pharmaceuticals publishes Information document in connection with forthcoming rights issue

Annexin Pharmaceuticals
Press release2026-06-05 08:30

Annexin Pharmaceuticals presenterar på Aktiedagarna i Stockholm den 10 juni

Annexin Pharmaceuticals